These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 28332991)
21. Favorable Outcome After Adjuvant Involved-Field Radiotherapy After Autologous Hematopoietic Stem-Cell Transplantation in Patients With High-Risk Relapsed/Refractory Lymphoma: A Single-Center Experience. Kaloyannidis P; Omari R; Eldebawy E; Al Shaibani E; Apostolidis J; Hindi T; Raslan H; Al Garni A; Al Buali A; Al Anezi K; Al Hashmi H Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e112-e119. PubMed ID: 33060051 [TBL] [Abstract][Full Text] [Related]
22. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma. Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199 [TBL] [Abstract][Full Text] [Related]
23. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712 [TBL] [Abstract][Full Text] [Related]
24. Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Trippett TM; Schwartz CL; Guillerman RP; Gamis AS; Gardner S; Hogan S; London WB; Chen L; de Alarcon P Pediatr Blood Cancer; 2015 Jan; 62(1):60-4. PubMed ID: 25308760 [TBL] [Abstract][Full Text] [Related]
25. Potential Benefit of Involved-Field Radiotherapy for Patients With Relapsed-Refractory Hodgkin's Lymphoma With Incomplete Response Before Autologous Stem Cell Transplantation. Levis M; Piva C; Filippi AR; Botto B; Gavarotti P; Pregno P; Nicolosi M; Freilone R; Parvis G; Gottardi D; Vitolo U; Ricardi U Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):14-22. PubMed ID: 27727134 [TBL] [Abstract][Full Text] [Related]
26. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM). Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263 [TBL] [Abstract][Full Text] [Related]
27. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease. Anselmo AP; Cavalieri E; Meloni G; Alimena G; Cantonetti M; Maurizi Enrici R; Tosti ME; Falchetto Osti M; Gianfelici V; Mandelli F Haematologica; 2002 May; 87(5):507-11. PubMed ID: 12010664 [TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma. Kelta M; Zekri J; Abdelghany E; Rehman JU; Khan ZA; Al-Saadi R; Dada R Tumori; 2018 Dec; 104(6):471-475. PubMed ID: 28009428 [TBL] [Abstract][Full Text] [Related]
29. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma. Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708 [TBL] [Abstract][Full Text] [Related]
30. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients. Akhtar S; El Weshi A; Abdelsalam M; Hussaini H; Janabi I; Rahal M; Maghfoor I Bone Marrow Transplant; 2007 Oct; 40(7):651-8. PubMed ID: 17660837 [TBL] [Abstract][Full Text] [Related]
31. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity. Hoppe BS; Moskowitz CH; Filippa DA; Moskowitz CS; Kewalramani T; Zelenetz AD; Yahalom J J Clin Oncol; 2008 Apr; 26(11):1858-64. PubMed ID: 18332466 [TBL] [Abstract][Full Text] [Related]
33. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168 [TBL] [Abstract][Full Text] [Related]
34. Rates and durability of response to salvage radiation therapy among patients with refractory or relapsed aggressive non-Hodgkin lymphoma. Tseng YD; Chen YH; Catalano PJ; Ng A Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):223-31. PubMed ID: 25835625 [TBL] [Abstract][Full Text] [Related]
35. A Prospective, Multicenter Study of Involved-Field Radiation Therapy With Autologous Stem Cell Transplantation for Patients With Hodgkin Lymphoma and Aggressive Non-Hodgkin Lymphoma (ALLG HDNHL04/TROG 03.03). Wirth A; Prince HM; Roos D; Gibson J; O'Brien P; Zannino D; Khodr B; Stone JM; Davis S; Hertzberg M Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1158-1166. PubMed ID: 30553941 [TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. Devillier R; Coso D; Castagna L; Brenot Rossi I; Anastasia A; Chiti A; Ivanov V; Schiano JM; Santoro A; Chabannon C; Balzarotti M; Blaise D; Bouabdallah R Haematologica; 2012 Jul; 97(7):1073-9. PubMed ID: 22271893 [TBL] [Abstract][Full Text] [Related]
37. High-dose chemotherapy and auto-SCT for relapsed and refractory Hodgkin's lymphoma patients refractory to first-line salvage chemotherapy but responsive to second-line salvage chemotherapy. Rauf MS; Maghfoor I; Elhassan TA; Akhtar S Med Oncol; 2015 Jan; 32(1):388. PubMed ID: 25429839 [TBL] [Abstract][Full Text] [Related]
38. High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma. Persky DO; Moskowitz CH; Filatov A; Saxena R; Cui H; Teruya-Feldstein J Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):35-40. PubMed ID: 19701081 [TBL] [Abstract][Full Text] [Related]
39. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Stiff PJ; Unger JM; Forman SJ; McCall AR; LeBlanc M; Nademanee AP; Bolwell BJ; Fisher RI; Biol Blood Marrow Transplant; 2003 Aug; 9(8):529-39. PubMed ID: 12931122 [TBL] [Abstract][Full Text] [Related]
40. Outcome after autologous stem cell transplantation in primary refractory or relapsed Hodgkin lymphoma-a long-term follow-up single center experience. Roerden M; Sökler M; Kanz L; Bethge W; Vogel W; Walz JS Ann Hematol; 2020 Feb; 99(2):265-276. PubMed ID: 31897675 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]